Inhaled lipopolysaccharide challenge as a human model to investigate potential therapies in Acute Respiratory Distress Syndrome
Latest Information Update: 03 Jul 2024
Price :
$35 *
At a glance
- Drugs Baricitinib (Primary)
- Indications Adult respiratory distress syndrome
- Focus Therapeutic Use
- 11 Jun 2024 Status changed from not yet recruiting to recruiting.
- 11 Jun 2024 Planned initiation date changed from 1 Jun 2024 to 1 Jul 2024.
- 11 Jun 2024 Status changed from recruiting to not yet recruiting.